SAN FRANCISCO, June 12 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic disease, announced today that CEO David Cory will deliver a corporate presentation at the 2008 BIO International Convention in San Diego. The DiObex presentation will take place on June 17 at 3:30 p.m. as part of the BIO Business Forum.
About DiObex
DiObex is a biotechnology company engaged in the development of novel products for metabolic disease. DIO-901 (very low dose glucagon) is in development in two convenient delivery forms for the prevention of nocturnal hypoglycemia induced by insulin intensification. Insulin-induced hypoglycemia, which occurs most frequently at night, is a major limitation in the aggressive management of hyperglycemia in diabetes patients. The DIO-901 disposable device will be applied before bedtime to provide continuous subcutaneous delivery of glucagon during the night. The DIO-901 extended release formulation will be delivered via auto injector before bedtime to slowly release glucagon during the night. DIO-901 has received Fast Track status from the FDA. For more information, visit http://www.diobex.com.
CONTACT: Keith Vendola, MD, Corporate Development of DiObex, Inc.,
+1-415-551-4115, keith@diobex.com
Web site: http://www.diobex.com/
